Bargain of the century or overpriced story stock? That is the question. Research on Sigma-1 was first published almost 40 years ago, so big pharma can't be unaware. Yet development of Sigma-1 antagonists for treatment of CNS diseases hasn't been a significant focus of big pharma R&D. Do you really believe big biotech/big pharma is either stupid or blinded by the not-invented-here syndrome? Anything is possible but...